Diasome
PrivateLast Round
Series C
Dec 7, 2023
Est. Valuation
$86M
Total Funding Raised
$43.7M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Diasome is a biotechnology company that develops innovative, cell-targeted therapies aimed at treating diabetes, obesity, and other metabolic disorders through proprietary liver-targeted insulins that help manage blood sugar levels effectively.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Diasome Comparables
Compare Diasome with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Adocia | 75% | |
| vTv Therapeutics Inc | 73% | |
| Oramed Pharmaceuticals Inc. | 73% |
Diasome Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Dec 7, 2023 | ||||
| Series B | Aug 26, 2022 | ||||
| Series B | Dec 23, 2020 | ||||
| Series A | Jul 5, 2017 | ||||
| Series B | Apr 15, 2008 |
Diasome Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Quaker Partners Management | Series B |
| Devon Park BioVentures | Series B |
| Black Beret Life Sciences | Series A |
| JDRF | Series A |
| Medicxi | Series A |
| McDonald Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 1394% MoM, reaching 2.3K.
- Dec 7, 2023
$10M round led by Eli Lilly and Company and Oramed Pharmaceuticals Inc.
Recent news
Latest coverage and updates
- hiresSep 15, 2026
Diasome hired Sangeeta Sawhney as Chief Medical Officer on Sep 15th '26.
Diasome Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Diasome's valuation, stock price, and market status.
Is Diasome a public or private company?
Diasome is a private company.
What is the current stock price of Diasome?
Diasome is a private company with no public stock price. No recent secondary market data is available.
How much is Diasome worth (valuation)?
Diasome's valuation is estimated at $86.0M based on funding round data.
Can I buy Diasome stock?
Diasome shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Diasome's last funding round?
Diasome's most recent funding round was Series C on August 26, 2022.
Who are the main investors in Diasome?
Key investors in Diasome include Quaker Partners Management, Devon Park BioVentures, Medicxi.
Will Diasome IPO soon?
No public IPO plans have been announced for Diasome.
How can I track Diasome secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Diasome's secondary market activity and sign up for updates.